IDEAYA Biosciences Management

Management criteria checks 1/4

IDEAYA Biosciences' CEO is Yujiro Hata, appointed in Jun 2015, has a tenure of 9.33 years. total yearly compensation is $6.00M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth €18.64M. The average tenure of the management team and the board of directors is 1.9 years and 6 years respectively.

Key information

Yujiro Hata

Chief executive officer

US$6.0m

Total compensation

CEO salary percentage10.0%
CEO tenure9.3yrs
CEO ownership0.8%
Management average tenure1.9yrs
Board average tenure6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Yujiro Hata's remuneration changed compared to IDEAYA Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$154m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$6mUS$598k

-US$113m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$3mUS$570k

-US$59m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$55m

Dec 31 2021US$4mUS$544k

-US$50m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$31m

Dec 31 2020US$2mUS$510k

-US$34m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$2mUS$457k

-US$42m

Sep 30 2019n/an/a

-US$40m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$38m

Dec 31 2018US$2mUS$420k

-US$34m

Compensation vs Market: Yujiro's total compensation ($USD6.00M) is above average for companies of similar size in the German market ($USD2.44M).

Compensation vs Earnings: Yujiro's compensation has increased whilst the company is unprofitable.


CEO

Yujiro Hata (50 yo)

9.3yrs

Tenure

US$5,995,440

Compensation

Mr. Yujiro S. Hata serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences, Inc. and has been its Chief Executive Officer, Presiden...


Leadership Team

NamePositionTenureCompensationOwnership
Yujiro Hata
President9.3yrsUS$6.00m0.80%
€ 18.6m
Andres Briseno
Principal Accounting Officer3.8yrsUS$1.41m0.029%
€ 674.5k
Michael White
Chief Scientific Officer2.9yrsUS$2.76m0%
€ 0
Darrin Beaupre
Chief Medical Officer1.9yrsUS$1.81m0%
€ 0
Paul Barsanti
Chief Technology Officer1.8yrsno datano data
Douglas Snyder
Senior VP & General Counselless than a yearno datano data
Francine Zelaya
Vice President & Head of Human Resourcesless than a yearno datano data
Mick O'Quigley
Chief of Staff & Clinical Development2.6yrsno datano data
Daniel Simon
Chief Business Officerless than a yearno datano data

1.9yrs

Average Tenure

57yo

Average Age

Experienced Management: 30J's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Yujiro Hata
President9.3yrsUS$6.00m0.80%
€ 18.6m
Wendy Yarno
Independent Director4.8yrsUS$358.02k0%
€ 0
Jeffrey Stein
Independent Director9yrsUS$363.02k0.0051%
€ 117.8k
Susan Kelley
Independent Director3.7yrsUS$349.52k0%
€ 0
Frank McCormick
Chair of Scientific Advisory Board5.7yrsno datano data
Scott William Morrison
Independent Director6.3yrsUS$364.52k0%
€ 0
Catherine Mackey
Independent Director2.5yrsUS$350.52k0%
€ 0
Trey Ideker
Member of Scientific Advisory Board8.4yrsno datano data
William Sellers
Member of Scientific Advisory Board5.7yrsno datano data
Elizabeth Swisher
Member of Scientific Advisory Board8.4yrsno datano data
Terry Rosen
Independent Chairman of the Board8.8yrsUS$369.52k0.019%
€ 449.5k
Malcolm Hampton
Independent Director4.3yrsUS$349.52k0%
€ 0

6.0yrs

Average Tenure

67.5yo

Average Age

Experienced Board: 30J's board of directors are considered experienced (6 years average tenure).